1-3 of 3
Anna Scuto, PhD
Close
Sort by
Journal Articles

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Tanya Siddiqi, MD, Anna Scuto, PhD, Jan H. Beumer, PharmD, PhD, Joo Y. Song, MD, Paul Frankel, PhD, Chris Ruel, MS, Jacob Cobb, BS, Brian F. Kiesel, BS, Dennis D. Weisenburger, MD, Kevin R. Kelly, MD PhD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, PhD MD, Edward M. Newman, PhD
Journal: Blood
Blood (2015) 126 (23): 2731.
https://doi.org/10.1182/blood.V126.23.2731.2731
Published: 2015
Journal Articles

Cyclin D1 Promotes Survival and Chemoresistance By Maintaining ATR and CHEK1 Signaling in TP53-Deficient Mantle Cell Lymphoma Cell Lines

Suchismita Mohanty, PhD, Thai Tran, Natalie Sandoval, Atish Mohanty, PhD, Victoria Bedell, Jun Wu, PhD, Charles Warden, MA, Anna Scuto, PhD, Joyce Collins, PhD, Dennis D. Weisenburger, MD, Vu N. Ngo, PhD
Journal: Blood
Blood (2014) 124 (21): 5197.
https://doi.org/10.1182/blood.V124.21.5197.5197
Published: 2014
Journal Articles

Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression.

Leo Kretzner, PhD, Anna Scuto, PhD, Agnes Juhasz, PhD, Richard Jove, PhD, Yun Yen, MD, Stephen J. Forman, MD, Mark Kirschbaum
Journal: Blood
Blood (2006) 108 (11): 2165.
https://doi.org/10.1182/blood.V108.11.2165.2165
Published: 2006